344905-99-3

Upstream product

• 34626-95-4 1,2:3,4-di-O-isopropylidene-β-D-psicofuranose 
• 874-60-2 4-methyl-benzoyl chloride 

Downstream Products

• 478487-91-1 4-Methyl-benzoic acid (3aR,4R,6R,6aR)-6-hydroxymethyl-6-methoxy-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester 
• 873957-41-6 1-[3',4'-O-isopropylidene-6'-O-(4-toluoyl)-β-D-psicofuranosyl]uracil 
• 873957-35-8 1-[3',4'-O-isopropylidene-6'-O-(4-toluoyl)-α-D-psicofuranosyl]uracil 
• 344906-05-4 1-[1',3'-anhydro-6'-O-(4,4'-dimethyoxytrityl)-β-D-psicofuranosyl]thymine 
• 344906-02-1 1-[1'-O-methylsulfonyl-3',4'-O-isopropylidene-6'-O-(4-toluoyl)-β-D-psicofuranosyl]thymine 
• 344906-03-2 1-[1'-O-methylsulfonyl-6'-O-(4-toluoyl)-β-D-psicofuranosyl]thymine 
• 344906-04-3 1-[1',3'-anhydro-6'-O-(4-toluoyl)-β-D-psicofuranosyl]thymine 
• 783322-66-7 9-[1',3'-O-anhydro-6'-O-(4,4'-dimethoxytrityl)-β-D-psicofuranosyl]-N⁶-(phenoxyacetyl)adenine 
• 783322-72-5 9-[1',3'-O-anhydro-6'-O-(4,4'-dimethoxytrityl)-β-D-psicofuranosyl]-N²-(N,N-(dimethylamino)methylene)guanine 
• 783322-68-9 9-[1'-O-methanesulfonyl-3',4'-O-acetyl-6'-O-(4-toluoyl)-β-D-psicofuranosyl]-N²-acetylguanine 
• 783322-65-6 9-[1',3'-O-anhydro-4',6'-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-psicofuranosyl]-N⁶-(phenoxyacetyl)-adenine 
• 783322-62-3 1-O-methanesulfonyl-2-O-methyl-3,4-O-acetyl-6-O-(4-toluoyl)-D-psicofuranose 
• 478487-96-6 9-[1'-O-methanesulfonyl-3',4'-O-acetyl-6'-O-(4-toluoyl)-β-D-psicofuranosyl]-N⁶-benzoyladenine 
• 478487-98-8 4-Methyl-benzoic acid (2R,3R,4R)-3,4-diacetoxy-5-bromo-5-methanesulfonyloxymethyl-tetrahydro-furan-2-ylmethyl ester 

Relevant academic research and scientific papers

Synthesis of anhydro psicofuranosyl nucleosides

Methyl 1-O-mesyl-5-O-toluoyl-β-D-psicofuranoside (5) was synthesised from the known 1,3;4,5-di-O-isopropylidene-β-D-psicofuranose (1) as a key carbohydrate precursor for the preparation of anhydro psicofuranosyl nucleosides. Transformation of 5 into aceta

ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA

The present invention includes methods of treating or preventing malaria by administering an anti-malarial effective amount of 6-substituted uridine derivatives to a subject need thereof. The invention also includes new 6-substituted uridine derivatives for use as therapeutics, in particular to treat malaria.

Conformation-specific cleavage of antisense oligonucleotide-RNA duplexes by RNase H

The North-form (3'-endo) constrained 1-(1',3'-O-anhydro-β-D-psicofuranosyl)thymine block, , was systematically incorporated at various sites, one at a time, into a set of four antisense oligonucleotides (AONs). The hybrids of these AONs with a matched